Prostate cancer treatment is selected from the cancer’s risk group and stage, the purpose of treatment, a person’s health and life expectancy, previous therapy, and the side effects that matter most to that person. Management can range from active surveillance with no immediate treatment to prostatectomy or radiation with curative intent, androgen-deprivation therapy and treatment intensification for advanced disease, or later-line targeted, radiopharmaceutical, chemotherapy and immunotherapy strategies. There is no single treatment that is best for every prostate cancer.
For suitable low-risk and selected favorable intermediate-risk prostate cancer, active surveillance can delay or avoid treatment while preserving the option of later cure. For localized cancers requiring treatment, radical prostatectomy and modern radiation are major curative-intent options. Higher-risk localized and locally advanced cancers often require multimodal treatment. Metastatic disease is usually treated systemically, with androgen deprivation forming the hormonal backbone and additional therapy selected according to disease state, prior treatment, symptoms, metastatic pattern and molecular findings.
01How Is Prostate Cancer Treatment Chosen?
Treatment starts with the disease state, not with the name of a procedure
Prostate cancer is not treated as one uniform disease.
Before choosing management, clinicians define several linked questions:
- Is the cancer localized, locally advanced, node-positive or metastatic?
- What is the Grade Group and other relevant pathology?
- What is the PSA level and overall risk classification?
- Is the goal surveillance, cure, long-term disease control, symptom relief or a combination?
- What is the patient’s estimated life expectancy and health status?
- What treatment has already been received?
- What adverse effects would have the greatest effect on quality of life?
For the anatomical foundation, review Prostate Cancer Stages. For the expected disease course, see Prostate Cancer Prognosis and Survival.
Why does risk group matter even when cancer is still localized?
Two cancers confined to the prostate can have very different biological risk.
A small Grade Group 1 cancer with favorable PSA characteristics may be appropriate for surveillance, while a Grade Group 4 or 5 cancer can require active treatment even when imaging shows no distant metastasis.
Risk classification therefore connects stage with grade, PSA and disease burden.
Does age determine treatment?
No.
Chronological age is only one part of treatment selection. Comorbidity, frailty, function and estimated life expectancy can be more important than age alone.
This matters because many curative treatments produce immediate adverse effects in order to prevent cancer-related problems that may otherwise arise years later.
Why does life expectancy matter?
The benefit of local treatment can take years to emerge.
A person with substantial life expectancy may have time to benefit from preventing recurrence or metastasis. A person with severe competing illnesses may be more likely to experience treatment toxicity than a meaningful survival benefit from aggressive local therapy.
Is prostate cancer treatment always intended to cure the cancer?
No.
Treatment intent changes across the disease pathway:
- active surveillance: defer treatment while preserving curative options;
- localized surgery or radiation: usually curative intent;
- salvage treatment: attempt to eradicate recurrent but still potentially controllable disease;
- metastatic systemic therapy: usually long-term disease control and survival prolongation rather than eradication;
- palliative treatment: relieve symptoms, prevent complications and preserve quality of life.
A treatment list without stage and risk context is clinically incomplete. The same therapy can have a very different role in low-risk localized cancer, high-risk localized cancer, biochemical recurrence, metastatic hormone-sensitive disease and metastatic castration-resistant disease.
02When Is Active Surveillance Used Instead of Immediate Treatment?
Active surveillance is an intentional management strategy
Active surveillance does not mean ignoring prostate cancer.
It is structured monitoring designed to avoid or delay the urinary, sexual and bowel effects of treatment in people whose cancer is unlikely to cause harm in the near term, while retaining the option of curative treatment if the disease is reclassified.
Current guideline frameworks generally use active surveillance as the standard approach for suitable low-risk disease and consider it for carefully selected favorable intermediate-risk disease.
The dedicated pathway is explained in Active Surveillance for Prostate Cancer.
What happens during active surveillance?
A surveillance program can include:
- serial PSA testing;
- clinical review;
- repeat MRI;
- repeat biopsy according to the surveillance protocol;
- assessment of PSA density and changes in disease volume;
- and reassessment of Grade Group if new tissue is sampled.
The purpose is not to treat a PSA number. It is to detect evidence that the cancer has become more clinically significant.
What can trigger a switch from surveillance to treatment?
A change in management may follow:
- pathological upgrading on repeat biopsy;
- increasing tumor extent;
- stage progression;
- MRI progression that is confirmed appropriately;
- or a patient’s informed decision to proceed with treatment.
PSA change is important, but PSA kinetics alone are not always enough to define biological progression.
How is watchful waiting different from active surveillance?
The treatment intent is different.
| Feature | Active surveillance | Watchful waiting |
|---|---|---|
| Primary aim | Delay or avoid treatment while preserving the option of later cure. | Avoid burdensome treatment when curative therapy is unlikely to provide meaningful benefit. |
| Typical setting | Favorable localized disease in a person with meaningful life expectancy. | Often limited life expectancy, major comorbidity or preference for symptom-directed care. |
| Monitoring | Structured PSA, clinical assessment, imaging and repeat biopsy according to protocol. | Individualized monitoring with treatment generally introduced for symptoms or clinically important progression. |
| If disease progresses | Curative-intent surgery or radiation may still be used. | Treatment is usually directed toward disease control or symptom relief rather than cure. |
Why can surveillance be safer than immediate treatment for some cancers?
Because treatment itself has consequences.
If a cancer has a low probability of causing symptoms, metastasis or death during the person’s relevant lifetime, immediate surgery or radiation can expose that person to urinary, sexual or bowel morbidity without a proportionate oncological benefit.
Does choosing surveillance mean treatment has failed to start?
No.
For an appropriately selected patient, surveillance is the management plan.
Active surveillance and watchful waiting should not be used as interchangeable labels. Active surveillance preserves a curative-intent pathway through structured monitoring. Watchful waiting is generally a symptom-directed strategy used when the burdens of curative treatment are expected to outweigh its likely long-term benefit.
03How Do Surgery and Radiation Treat Localized Prostate Cancer?
Radical prostatectomy removes the prostate and seminal vesicles
Radical prostatectomy is a curative-intent operation used in selected men with localized and some locally advanced prostate cancers.
The operation removes the prostate and seminal vesicles and then reconnects the bladder to the urethra. Pelvic lymph-node dissection may be performed when the predicted risk of nodal involvement justifies it.
Does robotic surgery remove less cancer than open surgery?
No.
“Robotic,” laparoscopic and open describe the surgical approach. The cancer operation is still a radical prostatectomy.
The quality of oncological resection, patient selection, pathological findings and surgeon experience are more important than treating the platform name as a different cancer therapy.
What are the major adverse outcomes after prostatectomy?
The most important long-term functional effects include:
- urinary incontinence or persistent urinary leakage;
- erectile dysfunction;
- loss of ejaculation and natural fertility;
- changes in orgasm;
- and less commonly bladder-neck contracture or urethral narrowing.
Recovery varies substantially according to age, baseline urinary and erectile function, nerve-sparing feasibility, tumor location, surgical technique and rehabilitation.
What does nerve-sparing prostatectomy mean?
The neurovascular bundles involved in erectile function lie close to the prostate.
When oncologically appropriate, surgeons may preserve one or both bundles. Nerve sparing is not guaranteed to preserve erections, and it may not be appropriate if doing so would compromise cancer control.
How does external-beam radiation treat prostate cancer?
External-beam radiation delivers ionizing radiation to the prostate and selected surrounding tissues from outside the body.
Modern treatment commonly uses image guidance with intensity-modulated or volumetric-modulated techniques so that dose conforms to the target while limiting exposure to the bladder, rectum and other normal structures.
What is hypofractionated radiation?
Hypofractionation uses a larger dose per treatment over fewer treatment sessions than conventional fractionation.
Moderate hypofractionation is established in modern prostate radiation, and selected patients may receive stereotactic body radiation therapy using an even smaller number of high-dose fractions.
What is brachytherapy?
Brachytherapy places a radiation source within or close to the prostate.
It can be delivered using:
- low-dose-rate brachytherapy: permanent radioactive seeds;
- high-dose-rate brachytherapy: temporary catheters through which a high-activity source is introduced.
Brachytherapy can be used alone in selected localized cancers or as a boost with external-beam radiation in higher-risk situations.
When is androgen deprivation added to radiation?
The answer depends strongly on risk group.
Radiation for favorable disease may not require ADT. As recurrence risk rises, short- or long-course ADT can be combined with radiation because the combined strategy improves disease control in appropriately selected intermediate- and high-risk settings.
What are the major adverse outcomes after radiation?
Potential effects include:
- urinary frequency, urgency or dysuria during treatment;
- rectal irritation, bowel urgency or bleeding;
- erectile dysfunction that may develop gradually;
- urinary obstruction or stricture in a minority of patients;
- and a small long-term risk of radiation-associated second malignancy.
Toxicity differs with baseline urinary function, treatment technique, dose, fractionation, target volume and whether ADT is added.
Are prostatectomy and radiation interchangeable?
No.
Both can be curative for localized prostate cancer, but they create different treatment pathways.
Surgery immediately provides whole-prostate pathology and is followed by a PSA that should fall to a very low or undetectable level. Radiation leaves the prostate in place, PSA declines differently, and recurrence is defined differently.
Their adverse-effect patterns also differ.
The correct comparison is not “which treatment has no side effects?” Every definitive local treatment creates trade-offs. The useful question is which cancer-control strategy offers an appropriate oncological benefit with the most acceptable urinary, sexual, bowel and general-health consequences for that individual.
What about focal therapy such as HIFU or cryotherapy?
Focal therapy attempts to ablate selected prostate tissue rather than treat the entire gland.
It can be attractive because of the possibility of reducing functional toxicity, but long-term comparative oncological evidence is less mature than for prostatectomy and radiation. Major guideline frameworks therefore restrict focal or whole-gland ablative approaches to clinical trials, registries or carefully governed programs rather than treating them as a universal replacement for established standard therapies.
04How Are Hormone Therapy and Systemic Treatments Used for Advanced Prostate Cancer?
Androgen deprivation therapy lowers testosterone signaling
Most prostate cancers initially depend substantially on signaling through the androgen receptor.
Androgen deprivation therapy, or ADT, reduces stimulation of this pathway by lowering testosterone production or suppressing androgen-receptor signaling.
Medical ADT commonly uses gonadotropin-releasing hormone agonists or antagonists. Surgical castration by orchiectomy provides another way to achieve durable testosterone suppression.
Is ADT alone enough for newly diagnosed metastatic prostate cancer?
For many medically fit patients, no.
Modern metastatic hormone-sensitive prostate cancer is generally treated with ADT plus treatment intensification rather than ADT alone.
Depending on the clinical setting, intensification may include an androgen-receptor pathway inhibitor and, for selected patients, chemotherapy as part of a combination strategy.
The exact regimen depends on:
- metastatic volume and distribution;
- symptoms;
- fitness for chemotherapy;
- cardiovascular and metabolic conditions;
- drug interactions;
- molecular findings;
- prior therapy;
- and patient preference.
What are androgen-receptor pathway inhibitors?
Androgen-receptor pathway inhibitors further suppress androgen signaling beyond standard testosterone-lowering therapy.
Agents used across advanced prostate-cancer settings include:
- abiraterone with corticosteroid support;
- enzalutamide;
- apalutamide;
- darolutamide;
- and other agents approved in specific jurisdictions and disease states.
They are not interchangeable in every patient because their evidence, interactions, toxicity profiles and regulatory indications differ.
When is chemotherapy used?
Taxane chemotherapy remains important in advanced prostate cancer.
Docetaxel can be incorporated into selected metastatic hormone-sensitive treatment strategies and is also used after progression in later disease states. Cabazitaxel is generally a later-line option after prior taxane and androgen-receptor pathway treatment in appropriate patients.
What does castration-resistant prostate cancer mean?
Castration-resistant prostate cancer is cancer that progresses despite testosterone being maintained at a castrate level.
Castration resistance does not mean androgen signaling is irrelevant and does not mean no treatments remain.
When distant metastases are present, the state is called metastatic castration-resistant prostate cancer.
Why does previous treatment matter so much in mCRPC?
Because many drugs historically studied in mCRPC are now used earlier in hormone-sensitive disease.
The next treatment therefore depends partly on what the tumor has already been exposed to and how it responded.
A patient who has previously received ADT plus an androgen-receptor pathway inhibitor is entering a different decision pathway from a patient whose cancer has progressed after ADT alone.
How can genomic testing change treatment?
Tumor and inherited genomic testing can identify alterations that affect both familial-risk counseling and treatment selection.
In advanced disease, alterations involving homologous-recombination repair genes—particularly BRCA1 and BRCA2—can create eligibility for PARP-inhibitor strategies in defined treatment settings.
Selected tumors with mismatch-repair deficiency or high microsatellite instability can also be candidates for immune-checkpoint therapy.
For the inherited-risk relationship, see BRCA1, BRCA2 and Prostate Cancer.
What is PSMA-targeted radioligand therapy?
PSMA-directed radioligand therapy uses a radioactive treatment linked to a molecule that targets prostate-specific membrane antigen on cancer cells.
Lutetium-177–PSMA-617 is used in selected PSMA-positive advanced prostate cancers according to prior treatment and current eligibility criteria.
This is systemic radiation therapy: the drug circulates through the body rather than irradiating the prostate from an external machine.
What is radium-223?
Radium-223 is an alpha-emitting radiopharmaceutical that targets areas of increased bone turnover.
It has a role in selected men with symptomatic bone-predominant metastatic castration-resistant disease without visceral metastases. It is not a general treatment for every metastatic pattern.
Does immunotherapy have a role?
Yes, but the role is selective.
Sipuleucel-T is an autologous cellular immunotherapy used in selected men with metastatic castration-resistant prostate cancer. Pembrolizumab can be considered for tumors with specific biomarkers such as mismatch-repair deficiency or high microsatellite instability.
Metastatic prostate cancer should not be reduced to “hormone therapy.” For many fit patients with newly diagnosed M1 disease, modern treatment intensification improves important outcomes compared with ADT alone. Later mCRPC treatment then depends heavily on which intensification therapies have already been used.
How is metastatic bone disease treated beyond anticancer therapy?
Bone metastases can cause pain, fracture, marrow problems or spinal-cord compression.
Management can include:
- effective systemic cancer treatment;
- analgesia;
- targeted external-beam radiation for painful lesions;
- bone-protective therapy in appropriate settings;
- orthopedic stabilization when fracture risk is substantial;
- and urgent treatment when spinal-cord compression is suspected.
The disease state is explained in Bone Metastases From Prostate Cancer.
05What Side Effects and Trade-Offs Matter When Comparing Prostate Cancer Treatments?
Different treatments exchange different types of risk
A useful treatment comparison has at least two axes:
- oncological benefit: what the treatment is expected to prevent or control;
- treatment burden: what urinary, sexual, bowel, hormonal, metabolic or general-health effects the treatment may create.
A technically effective therapy can still be a poor fit if its expected benefit is small relative to its toxicity in that specific patient.
| Management strategy | Where it commonly fits | Main intended benefit | Important limitations | Characteristic adverse outcomes / burdens |
|---|---|---|---|---|
| Active surveillance | Suitable low-risk and selected favorable intermediate-risk localized cancer. | Avoid or delay treatment toxicity without losing the opportunity for cure if disease is reclassified. | Requires structured follow-up; some cancers are reclassified and later require treatment. | Repeat testing/biopsy burden, uncertainty or anxiety, risk of progression if surveillance is inadequate. |
| Radical prostatectomy | Selected localized and some locally advanced disease in patients fit for surgery. | Remove the prostate with curative intent and obtain definitive surgical pathology. | Operation does not guarantee cure; adverse pathology or recurrence may require additional therapy. | Urinary incontinence, erectile dysfunction, anejaculation/infertility, perioperative complications. |
| External-beam radiation | Localized through locally advanced disease; selected metastatic settings; palliation of metastases. | Curative local control or symptom control depending on setting. | Treatment field/dose and need for ADT vary by risk; salvage after definitive radiation is more selective. | Urinary irritation, bowel toxicity, erectile dysfunction, fatigue, uncommon late strictures/bleeding, small second-cancer risk. |
| Brachytherapy | Selected localized disease; can be used as a boost in some higher-risk cases. | Deliver a high radiation dose directly within the prostate. | Not appropriate for every prostate size, urinary-function profile or risk state. | Urinary frequency/obstruction, dysuria, erectile dysfunction; procedure-specific anesthesia/instrumentation burden. |
| ADT | With radiation in defined higher-risk localized disease; recurrent, metastatic and castration-resistant pathways. | Suppress androgen signaling and slow prostate-cancer growth. | Usually not curative by itself in metastatic disease; resistance can emerge. | Hot flashes, loss of libido, erectile dysfunction, fatigue, muscle loss, increased fat mass, bone loss and metabolic effects. |
| AR-pathway inhibitor | Several metastatic hormone-sensitive, nonmetastatic CRPC and mCRPC settings depending on the agent. | Intensify androgen-pathway suppression and delay progression. | Choice depends on prior therapy, comorbidity, interactions, disease state and drug-specific evidence. | Fatigue and agent-specific cardiovascular, metabolic, neurologic or hepatic adverse effects. |
| Taxane chemotherapy | Selected metastatic hormone-sensitive disease and later advanced/castration-resistant disease. | Systemic cytotoxic control and survival prolongation in appropriate settings. | Requires sufficient physiologic reserve; sequencing depends on prior treatment. | Myelosuppression, infection risk, neuropathy, fatigue, hair loss and other chemotherapy toxicities. |
| PARP-inhibitor strategy | Defined advanced-disease settings with qualifying homologous-recombination repair alterations, especially BRCA1/2. | Exploit a specific DNA-repair vulnerability. | Not appropriate for all tumors; exact indication depends on mutation, prior therapy and combination. | Anemia and other cytopenias, fatigue, nausea and agent-specific toxicity. |
| PSMA radioligand therapy | Selected PSMA-positive advanced prostate cancer according to treatment history and eligibility. | Deliver systemic radiation to PSMA-expressing cancer. | Requires appropriate PSMA imaging/eligibility; not all tumors express sufficient target. | Dry mouth, fatigue, nausea and hematologic toxicity among recognized adverse effects. |
Why is urinary function important before treatment?
Baseline function changes the meaning of toxicity.
A man with significant obstruction before treatment may tolerate certain strategies differently from a man with excellent urinary function. Prostate size, prior procedures, bladder function and symptom severity can all influence treatment planning.
Why is sexual function important before treatment?
Erectile recovery after surgery and erectile outcomes after radiation depend partly on baseline function.
Age, diabetes, vascular health, nerve-sparing feasibility, ADT exposure and pre-treatment erectile function all modify expected outcomes.
Why does ADT require broader health monitoring?
Long-term testosterone suppression affects more than sexual function.
Clinicians may need to consider:
- bone density and fracture risk;
- body composition and muscle mass;
- glucose metabolism;
- lipids;
- cardiovascular risk;
- fatigue and physical function;
- and emotional or cognitive symptoms.
Can side effects be treated?
Many can be reduced, rehabilitated or actively managed, although not every effect is reversible.
Examples include:
- pelvic-floor rehabilitation for urinary recovery;
- erectile-dysfunction rehabilitation and treatment;
- exercise to protect muscle, metabolic health and bone during ADT;
- bone-health assessment and treatment when indicated;
- management of radiation-associated urinary or bowel symptoms;
- and supportive or palliative care for advanced disease.
Why is survivorship part of treatment rather than an afterthought?
Because successful cancer control can create years or decades of life with treatment effects.
Long-term care therefore includes cancer surveillance, urinary and sexual function, bone and metabolic health, psychological health, cardiovascular risk and management of late treatment effects.
The next step in this pathway is Prostate Cancer Survivorship.
Urgent symptoms can override the usual pace of treatment selection. New leg weakness, loss of bladder or bowel control, severe progressive back pain, acute urinary retention, major bleeding or other signs of a cancer-related emergency require prompt clinical assessment rather than routine treatment comparison.
→Prostate Cancer Treatment by Clinical State
| Clinical state | Typical management direction | What usually drives escalation | Core limitation to remember |
|---|---|---|---|
| Low-risk localized | Active surveillance is standard for suitable patients; definitive local therapy remains available when indicated or preferred. | Pathological upgrading, greater disease extent, stage progression or informed patient choice. | Not every PSA fluctuation equals clinically meaningful progression. |
| Favorable intermediate-risk | Selected patients may undergo surveillance; others receive prostatectomy or radiation. | Grade Group, percentage pattern 4, tumor burden, imaging, PSA density and life expectancy. | “Intermediate risk” is heterogeneous. |
| Unfavorable intermediate-risk | Definitive local treatment; radiation commonly incorporates short-course ADT according to the exact setting. | Multiple intermediate-risk factors, Grade Group 3 or greater disease burden. | Surveillance is generally not the default strategy. |
| High-risk / locally advanced | Multimodal curative-intent treatment: radiation plus longer-course ADT or surgery in selected patients with expectation that additional therapy may be needed. | Stage, Grade Group, PSA, nodal risk and adverse pathology. | One treatment modality may not be enough. |
| Biochemical recurrence | Risk-adapted salvage therapy, monitoring or systemic treatment depending on the original treatment and recurrence pattern. | PSA kinetics, interval to recurrence, Grade Group, imaging and previous local therapy. | A rising PSA is not automatically visible metastatic disease. |
| Metastatic hormone-sensitive | ADT plus treatment intensification for most fit patients; local prostate radiation in selected low-volume de novo metastatic disease. | Volume, symptoms, comorbidity, fitness, genomic findings and treatment access. | ADT alone is no longer sufficient for many fit patients. |
| Metastatic castration-resistant | Continue castrate testosterone and select subsequent systemic therapy according to prior exposure, symptoms, metastatic pattern and biomarkers. | Prior ARPI/taxane use, BRCA/HRR status, PSMA expression, visceral disease and clinical fitness. | There is no universal sequence for every patient. |
Key Points
- Prostate cancer treatment is selected by risk, stage, life expectancy, health, treatment intent and patient preference.
- Active surveillance is an active management strategy, not absence of care.
- Suitable low-risk and selected favorable intermediate-risk cancers can often begin with surveillance.
- Radical prostatectomy and radiation are major curative-intent treatments for localized prostate cancer.
- High-risk localized and locally advanced disease frequently require multimodal treatment.
- Surgery and radiation have different urinary, sexual, bowel and salvage-treatment pathways.
- ADT is a hormonal backbone, not a universal stand-alone treatment for all advanced disease.
- Many fit patients with newly diagnosed metastatic disease benefit from treatment intensification beyond ADT alone.
- Prior therapy becomes increasingly important once prostate cancer becomes castration-resistant.
- BRCA/HRR status, mismatch-repair biology and PSMA expression can affect advanced-treatment selection.
- Focal therapy should not be treated as an established replacement for prostatectomy or radiation across all localized cancers.
- Adverse effects are part of treatment selection, not a secondary discussion after the decision has been made.
- Long-term survivorship begins at treatment planning because urinary, sexual, metabolic, bone and psychological consequences can persist after cancer control.
Clinical bottom line: prostate cancer treatment is a sequence of decisions rather than a contest between surgery and radiation. Favorable localized disease may be monitored safely in selected patients; clinically significant localized disease can often be treated with curative-intent surgery or radiation; high-risk disease frequently requires combined treatment; and metastatic disease is managed primarily with systemic therapy built around androgen suppression and modern treatment intensification. The appropriate strategy changes with stage, Grade Group, PSA profile, tumor burden, previous therapy, molecular findings, health, life expectancy and the adverse effects the patient is willing to accept.
Medical disclaimer: This article provides general medical education about prostate cancer treatment. It does not select a treatment for an individual patient. Treatment decisions require review of pathology, Grade Group, PSA and PSA kinetics, imaging, stage, risk group, previous treatment, genomic findings, urinary and sexual function, medications, cardiovascular and metabolic health, frailty, life expectancy and personal preferences with the treating urology, radiation-oncology and/or medical-oncology team.
For the disease framework, return to the Prostate Cancer hub. For the page immediately preceding this guide, review Prostate Cancer Prognosis and Survival. The surveillance pathway continues in Active Surveillance for Prostate Cancer, while long-term care after treatment is covered in Prostate Cancer Survivorship. Advanced disease is expanded in Metastatic Prostate Cancer and Metastatic Castration-Resistant Prostate Cancer.
Evidence Sources
- European Association of Urology — Prostate Cancer: Treatment. Risk-adapted management, active surveillance, radical prostatectomy, radiotherapy, androgen-deprivation therapy, metastatic treatment and salvage pathways.
- National Cancer Institute — Prostate Cancer Treatment (PDQ), Health Professional Version. Stage-based treatment options and evidence across surveillance, surgery, radiation, hormone therapy and advanced disease.
- National Cancer Institute — Prostate Cancer Treatment (PDQ), Patient Version. Patient-facing overview of active surveillance, surgery, radiation, hormone therapy, chemotherapy, targeted therapy and immunotherapy.
- American Society of Clinical Oncology — Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: Living Guideline. Current sequencing of systemic therapy according to previous treatment, genomics and clinical state.
- ASCO Living Guideline, Version 2026.1.4 — current 2026 evidence update for systemic treatment of metastatic castration-resistant prostate cancer.
